Resources
310 Results (showing 61 - 70)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 9/6/2022 (updated 3/27/2024)
On Monday, the U.S. Department of Health & Human services announced approximately $4 million to four awardees through its Rural Maternity and Obstetrics Management Strategies Program to enhance access to and coordination of obstetric and maternal care in rural communities.
Posted 9/7/2022 (updated 3/27/2024)
During this webinar, Claudia Jasso, Chief Development Officer for RCORP Implementation grantee, Amistades, Inc. and Janet Ojeda, JBS International Technical Expert Lead will present an overview of the unique cultural context, core beliefs, and value systems that should be at the heart of understanding and engaging with Latino populations. Presenters will discuss how racial inequity, assimilation, risk factors, and historical and immigration trauma have created a landscape where there is a critical need for person centered, culturally respectful and relevant mental health and SUD/OUD supports and service delivery for Latino people. All RCORP grantees, consortium members, and key community partners are welcome to attend.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 2/28/2023 (updated 3/27/2024)
Harm in Behavioral Health: The Ethical Necessity for Multicultural Practices in Behavioral Health Programs webinar training material.
Posted 3/21/2023 (updated 3/27/2024)
Researchers at Indiana University conducted one-on-one interviews with clinical providers and other stakeholders in the recovery arena to better understand the slow uptake of the drug most used to treat opioid use disorder. Biases against buprenorphine was the most consistent theme, though the reason for bias differed amongst stakeholders. Clinical providers and behavioral health care providers preferred the abstinence approach rather than use of medications.
Posted 10/12/2022 (updated 3/27/2024)
Monday, October 3rd was Child Health Day 2022, an observance and recommitment to the health and well-being of children and their families.
Posted 3/7/2023 (updated 3/27/2024)
Training material Pre-Addiction: Research Needed to Evaluate its Public Health Value
Posted 3/29/2023 (updated 3/27/2024)
The study has identified inherited genetic markers that are commonly inherited across addiction disorders, regardless of the substance being used. It also reinforces the role of the dopamine system within substance use disorders. This may help to further understand and implement personalized interventions for people with substance use disorders by taking into account a person's biology, environment, and lived experience.
Posted 5/31/2022 (updated 3/27/2024)
With facts and figures about health status, behavioral risk factors, mortality, and access to care, the resource aims to inform rural health policy for four states – Arizona, California, New Mexico, and Texas – along the U.S. southern border. The chartbook is a collaboration between the FORHP-supported Rural & Minority Health Research Center and the National Rural Health Association.